Trevi Therapeutics (TRVI) Preferred Dividend Payments (2018 - 2019)
Trevi Therapeutics (TRVI) posted quarterly Preferred Dividend Payments of $686000.0 for Q2 2019, down 46.95% year-over-year from $1.3 million in Q2 2018, and down 55.83% quarter-over-quarter from $1.6 million in Q1 2019.
Trevi Therapeutics (TRVI) Preferred Dividend Payments (2018 - 2019) Analysis & Trends
Trevi Therapeutics' Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at $686000.0 for Q2 2019.
- In Q2 2019, Preferred Dividend Payments fell 46.95% year-over-year to $686000.0; the TTM figure through Dec 2019 stood at $2.2 million (up 171.97% YoY), while the FY2019 annual figure was $2.2 million, up 705.14% from the prior year.
- Preferred Dividend Payments for Q2 2019 stood at $686000.0, down from $1.6 million in the prior quarter.
- The five-year high for Preferred Dividend Payments was $1.6 million in Q1 2019, with the low at -$4.3 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 686,000.00 |
| Mar 31, 2019 | 1.55 Mn |
| Dec 31, 2018 | -4.31 Mn |
| Sep 30, 2018 | 96,000.00 |
| Jun 30, 2018 | 1.29 Mn |
| Mar 31, 2018 | -195,000.00 |